CPT-11's Effectiveness Against Pediatric Tumors
Author Information
Author(s): G Vassal, MJ Terrier-Lacombe, MC Bissery, AM Venuat, F Gyergyay, J Benard, J Morizet, I Boland, P Ardouin, B Bressac-de-Paillerets, A Gouyettel
Primary Institution: Institut Gustave-Roussy
Hypothesis
CPT-11, a DNA-topoisomerase I inhibitor, will show therapeutic activity against pediatric peripheral primitive neuroectodermal tumors and neuroblastoma xenografts.
Conclusion
CPT-11 demonstrated significant anti-tumor activity against pPNET and neuroblastoma xenografts, warranting further clinical development in pediatric oncology.
Supporting Evidence
- CPT-11 induced 100% tumor-free survivors in mice with the pPNET SK-N-MC xenograft.
- Complete tumor regressions were observed in 38-100% of neuroblastoma xenografts.
- The optimal dosage for CPT-11 was determined to be 40 mg/kg daily for 5 days.
- Other anti-cancer drugs showed less efficacy compared to CPT-11 in the same models.
Takeaway
CPT-11 is a new medicine that helps fight certain childhood cancers by making the cancer cells die. It worked really well in mice with these cancers.
Methodology
The study involved testing CPT-11 on various pediatric tumor xenografts in athymic mice, evaluating tumor regression and growth delay.
Limitations
The study was conducted in mice, which may not fully replicate human responses to CPT-11.
Participant Demographics
The study involved female SPF-Swiss nude mice aged 6-8 weeks.
Want to read the original?
Access the complete publication on the publisher's website